NYSE:NVS - Novartis Stock Price, Forecast & News

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis declared an annual dividend on Monday, February 3rd. Shareholders of record on Wednesday, March 4th will be given a dividend of $3.0425 per share on Thursday, March 12th. This represents a yield of 2%. The ex-dividend date is Tuesday, March 3rd. This is a positive change from Novartis's previous annual dividend of $2.86. View Novartis' Dividend History.

Novartis AG (NYSE:NVS) posted its quarterly earnings results on Tuesday, October, 22nd. The company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.31 by $0.10. The firm had revenue of $12.17 billion for the quarter, compared to analyst estimates of $11.67 billion. Novartis had a net margin of 24.73% and a return on equity of 23.39%. Novartis's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.32 earnings per share. View Novartis' Earnings History.

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Novartis.

9 brokers have issued 1-year price targets for Novartis' shares. Their forecasts range from $79.16 to $105.00. On average, they expect Novartis' share price to reach $91.67 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Novartis.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Headlines about NVS stock have been trending neutral on Tuesday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novartis earned a news sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Novartis.

Novartis saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,650,000 shares, an increase of 17.7% from the January 15th total of 3,100,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 0.2% of the company's shares are sold short. View Novartis' Current Options Chain.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Pfizer (PFE), AT&T (T), Intel (INTC), Cisco Systems (CSCO), NVIDIA (NVDA), Merck & Co., Inc. (MRK) and Verizon Communications (VZ).

Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (0.51%), Loomis Sayles & Co. L P (0.45%), Bank of America Corp DE (0.41%), Renaissance Technologies LLC (0.29%), Mawer Investment Management Ltd. (0.26%) and FMR LLC (0.26%).

NVS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., State Street Corp, Fort Washington Investment Advisors Inc. OH, Manning & Napier Group LLC, Partner Fund Management L.P., Boston Partners and Schafer Cullen Capital Management Inc.

NVS stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Jennison Associates LLC, Renaissance Technologies LLC, Westfield Capital Management Co. LP, Bank of America Corp DE, Madison Asset Management LLC, Bain Capital Public Equity Management II LLC and Magnetar Financial LLC.

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $97.28.

Novartis has a market capitalization of $222.95 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.View Additional Information About Novartis.

The official website for Novartis is http://www.novartis.com/.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]